Litigation Details for CELGENE CORPORATION v. BRECKENRIDGE PHARMACEUTICAL, INC. (D.N.J. 2018)
✉ Email this page to a colleague
CELGENE CORPORATION v. BRECKENRIDGE PHARMACEUTICAL, INC. (D.N.J. 2018)
Docket | ⤷ Try a Trial | Date Filed | 2018-10-05 |
Court | District Court, D. New Jersey | Date Terminated | 2019-02-06 |
Cause | 15:1126 Patent Infringement | Assigned To | Esther Salas |
Jury Demand | None | Referred To | Michael A. Hammer |
Patents | 9,993,467 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in CELGENE CORPORATION v. BRECKENRIDGE PHARMACEUTICAL, INC.
Details for CELGENE CORPORATION v. BRECKENRIDGE PHARMACEUTICAL, INC. (D.N.J. 2018)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | 1 | expiration of United States Patent No. 9,993,467 (the “’467 patent” or “the patent-in-suit”) owned by Celgene… 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C… The Patent-in-Suit 6. On June 12, 2018, the United States Patent and Trademark…of the ’467 patent, constitutes infringement of one or more of the claims of that patent under 35 U.S.C…infringement of any claim of the patent-in-suit, until after the expiration of the patent-in-suit, or any later | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |